Meeting
2024 ASCO Annual Meeting
CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL.
Authors
Mazyar Shadman
Fred Hutchinson Cancer Research Center, Seattle, WA
Mazyar Shadman , Arnon P. Kater , Jennifer Ann Woyach , Jianyong Li , Talha Munir , Tommi Salmi , Patrick Phuong , Tian Tian , Piers Patten
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Clinical Trial Registration Number
NCT06073821
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS7087)
DOI
10.1200/JCO.2024.42.16_suppl.TPS7087
Abstract #
TPS7087
Poster Bd #
68a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.
First Author: Christopher Flowers
Poster
2022 ASCO Annual Meeting
Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.
First Author: Wojciech Jurczak
Poster
2019 ASCO Annual Meeting
ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
First Author: Peter Hillmen
Poster
2019 ASCO Annual Meeting
Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA.
First Author: Geoffrey J Lindeman